Developer docs
API playgroundTry for free, no card

Search company profiles

Cellex

Full company profile

uuid000aspm

Namestring
Cellex
Legal namestring
Cellex Cell Professionals GmbH
Websiteurl
cellex.me
Company typeenum
Private
Founded yearint
2001
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersKöln, Germany
HQ citystring
Köln
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices7 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
cell therapy manufacturing, contract development manufacturing, gene therapy CDMO, ATMP manufacturing services, cell collection logistics
Industry2 codes
PRIMARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)
NAICS code1 code
  • Blood and Organ Banks621991
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Cell and Gene Therapy CDMO Services
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Manufacturing Services (CDMO)
TypeManaged Services
Description

Cellex generates revenue through contract manufacturing services as a Contract Development and Manufacturing Organization (CDMO). Services include manufacturing of ATMPs/CGT products for clinical trials and commercial use, process development and optimization, process validation, starting material collection, consulting and support from preclinical development to commercialization, GMP audits, and supply chain and logistics. Revenue is generated through long-term project contracts with pharmaceutical companies, biotech firms, and academic institutions from preclinical stages through commercial production.

cellex.me
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Cell Community
Description

Donor pool database providing customized starting material for cell therapy development, research, clinical trials, and commercial use.

cellex.me
+3 more records
Core offering1 text field

Cellex is a full-service Contract Development and Manufacturing Organization (CDMO) for cell and gene therapy products, providing GMP-compliant manufacturing of ATMPs/CGT products for clinical trials and commercial use. The company offers autologous and allogeneic cell collection from donors (Cell Community donor pool, apheresis center), process development, optimization, validation, genetic modification, fill & finish, cryopreservation, QP batch certification, temperature-controlled logistics via CMT, and regulatory consultancy including GMP audits for pharma, biotech, and academic clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 3 approved CAR-T therapies manufactured in Cellex facilities in Europe
+5 more records
Product overview1 text field

Cellex is a full-service CDMO (Contract Development and Manufacturing Organization) for cell and gene therapy products based in Germany. The company operates a platform-plus-services model consisting of: (1) Starting Material / Cell Products including the Cell Community donor pool and Apheresis Center for collecting leukopaks, mobilized blood stem cells, bone marrow, and whole blood; (2) Manufacturing of ATMPs/CGT Products with GMP-compliant facilities producing 4 final drug products (FDPs) and 7 cellular intermediates; (3) Supply Chain & Logistics (CMT) for temperature-controlled transport and tracking; (4) Consultancy & Audits for regulatory compliance and GMP processes; and (5) Supporting initiatives including the Cellex Foundation and annual Cellex Symposium. The company leverages over 10 years of experience and has been involved in manufacturing 3 commercially approved CAR-T therapies in Europe.

Product and service4 records
1Starting Material / Cell Products (with Cell Community donor pool and Apheresis Center)
CategoryStarting Material / Cell Collection
Description

High-quality human starting materials for cell therapies including leukopaks, G-CSF mobilized blood stem cells, cord blood, bone marrow samples, and whole blood, collected under GxP conditions and customizable based on donor specifications (age, gender, BMI, HLA data, infectious disease markers). Used by pharma, biotech, academic, and transplant center clients for research, clinical trials, and commercial cell therapy production.

2Manufacturing of ATMPs/CGT Products
CategoryContract Manufacturing (CDMO)
Description

GMP-compliant contract development and manufacturing of cell and gene therapy products (ATMPs/CGT) for clinical trials and commercial use. Includes process development and optimization, process validation, genetic modification using viral vectors or CRISPR/Cas9, cell expansion, fill & finish, cryopreservation, and Qualified Person (QP) batch certification. Cellex currently manufactures 4 final drug products (FDPs) and 7 cellular intermediates for clients.

3Supply Chain & Logistics (CMT)
CategoryLogistics & Distribution Services
Description

Central coordination through Cellex Manufacturing Transports and Logistics (CMT) provides product labeling, release documentation, archiving management, and temperature-controlled transport at ambient, +2 to +8°C, +15 to +25°C, -80°C, and -196°C with 24/7 shipment tracking, GDP/GxP compliance, and validated transport processes. Over 40,000 cell transport shipments have been completed.

4Consultancy & Audits
CategoryRegulatory Consulting
Description

Regulatory consulting and audit services covering GMP/GxP compliance, EMA and FDA guidelines, genetic manipulation with viral vectors and CRISPR/Cas9, audit services for apheresis centers, quality management system creation, and clinical trial planning support. Over 150 audits have been carried out by Cellex's consulting team.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-05
Description

Cellex completed GMP technology transfer to Cellex Cell Professionals GmbH for Swarm Oncology, securing German Manufacturer's Authorisation enabling GMP-compliant clinical-grade drug product manufacturing. This partnership positions Swarm Oncology to initiate its first-in-human clinical study for T cell therapies targeting advanced solid cancers.

Strategic tierMinorTypeOthersAnnounced on2025-01-01
Description

Catalent expanded its agreement with Cartherics for iPSC-derived CAR-NK cell therapies. While this partnership does not directly involve Cellex, it is noted as a key development in the broader cell and gene therapy CDMO market that Cellex operates within.

Strategic tierMinorTypeOthersAnnounced on2025-01-01
Description

Oxford Biomedica entered a multi-year supply agreement with Bristol Myers Squibb for lentiviral vectors for CAR-T programs. This is noted as a key development in the broader cell and gene therapy CDMO market context.

Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2021-01-01
Description

AvenCell Therapeutics was co-founded in 2021 by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics, with registered offices in Boston, USA and Dresden, Germany. The company focuses on the development of allogeneic universal CAR-T cell therapies for immuno-oncology. Cellex participates as a manufacturing and strategic partner in this joint venture.

Recent move13 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Lonza is one of the world's largest CDMOs with a substantial cell and gene therapy manufacturing offering, including autologous and allogeneic capabilities. It is a direct competitor for Cellex's commercial and clinical-scale cell therapy manufacturing business, with broader geographic reach and significantly larger capacity.

TypeBroad incumbent
Description

Catalent (acquired by Novo Holdings in 2024 for ~$16.5B) is a major global CDMO with dedicated cell therapy manufacturing services. It competes head-to-head with Cellex for CAR-T and other cell therapy sponsors, and was specifically cited as a comparable market participant in Cellex's competitive landscape.

TypeDirect peer
Description

Oxford Biomedica is a UK-based cell and gene therapy CDMO specializing in lentiviral vector manufacturing and has signed multi-year supply agreements (e.g., with Bristol Myers Squibb for CAR-T). It is one of the closest European peers to Cellex, operating in the same niche with similar CAR-T focus.

TypeBroad incumbent
Description

Fujifilm Diosynth is a large global CDMO that has invested in cell and gene therapy manufacturing capacity, including viral vector and cell therapy services. It competes with Cellex for large pharma cell therapy manufacturing contracts.

TypeBroad incumbent
Description

Thermo Fisher's pharma services division (including legacy Patheon) offers cell therapy and viral vector CDMO capabilities. As one of the largest life sciences tools and services providers, it competes with Cellex on integrated cell therapy offerings, particularly for clinical and commercial-scale programs.

TypeBroad incumbent
Description

Charles River provides cell and gene therapy CDMO services through its Biologics Solutions segment. It serves similar biotech and pharma customers developing advanced therapies, including starting material and manufacturing services comparable to Cellex's offerings.

TypeDirect peer
Description

AGC Biologics is a global CDMO with cell and gene therapy manufacturing capabilities, including autologous and allogeneic services. It serves as a direct mid-sized competitor to Cellex in the European and global cell therapy CDMO market.

TypeBroad incumbent
Description

WuXi AppTec's Advanced Therapies unit is a major cell and gene therapy CDMO with large-scale manufacturing capabilities. It competes with Cellex for global cell therapy programs, though geopolitical considerations may limit overlap with certain Western sponsors.

TypeDirect peer
Description

Rentschler Biopharma is a German/European CDMO with cell and gene therapy capabilities, including viral vector manufacturing. It is a geographically and operationally similar mid-sized European peer to Cellex.

10Minaris Regenerative Medicine
TypeDirect peer
Description

Minaris (formerly Hitachi Chemical Advanced Therapeutics Solutions) is a dedicated cell therapy CDMO focused on autologous and allogeneic cell therapy manufacturing. It is a closely comparable mid-sized specialist peer to Cellex.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers6 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellex

Cell and Gene Therapy CDMO Servicescellex.me

Cellex firmographics

Firmographics
Name
Cellex
Legal name
Cellex Cell Professionals GmbH
Website
https://cellex.me
Company type
Private
Founded year
2001
Operating status
Operating
Headcount range
101–250 employees
Ownership category
akta.pro rank

Cellex industry classification

Industry
Product category
Cell and Gene Therapy CDMO Services
NAICS
Blood and Organ Banks (621991)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAGAA
Cell Therapy CDMO (Autologous/Allogeneic Manufacturing)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
SECONDARYHLAAAKAC
Cell Therapy Manufacturing Services (GMP, autologous/allogeneic)

Keywords

  • Cell therapy manufacturing
  • Contract development manufacturing
  • Gene therapy CDMO
  • ATMP manufacturing services
  • Cell collection logistics

Where Cellex is headquartered

Location

Headquarters

HQ city
Köln
HQ country
Germany
HQ region
Europe

Offices7 records

Markets served

Cellex business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

  1. Contract Manufacturing Services (CDMO): Cellex generates revenue through contract manufacturing services as a Contract Development and Manufacturing Organization (CDMO). Services include manufacturing of ATMPs/CGT products for clinical trials and commercial use, process development and optimization, process validation, starting material collection, consulting and support from preclinical development to commercialization, GMP audits, and supply chain and logistics. Revenue is generated through long-term project contracts with pharmaceutical companies, biotech firms, and academic institutions from preclinical stages through commercial production.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Cellex product offering

Product offering

Core offering

Cellex is a full-service Contract Development and Manufacturing Organization (CDMO) for cell and gene therapy products, providing GMP-compliant manufacturing of ATMPs/CGT products for clinical trials and commercial use. The company offers autologous and allogeneic cell collection from donors (Cell Community donor pool, apheresis center), process development, optimization, validation, genetic modification, fill & finish, cryopreservation, QP batch certification, temperature-controlled logistics via CMT, and regulatory consultancy including GMP audits for pharma, biotech, and academic clients.

Product overview

Cellex is a full-service CDMO (Contract Development and Manufacturing Organization) for cell and gene therapy products based in Germany. The company operates a platform-plus-services model consisting of: (1) Starting Material / Cell Products including the Cell Community donor pool and Apheresis Center for collecting leukopaks, mobilized blood stem cells, bone marrow, and whole blood; (2) Manufacturing of ATMPs/CGT Products with GMP-compliant facilities producing 4 final drug products (FDPs) and 7 cellular intermediates; (3) Supply Chain & Logistics (CMT) for temperature-controlled transport and tracking; (4) Consultancy & Audits for regulatory compliance and GMP processes; and (5) Supporting initiatives including the Cellex Foundation and annual Cellex Symposium. The company leverages over 10 years of experience and has been involved in manufacturing 3 commercially approved CAR-T therapies in Europe.

Differentiator

Problem solved

Functional benefit

Brands

  • Cell Community: Donor pool database providing customized starting material for cell therapy development, research, clinical trials, and commercial use.
  • Cellex Cell Manufacturing Plant (CCMP)
  • Cellex Foundation
  • Cellex Manufacturing Transports and Logistics (CMT)

Products and services

  • Starting Material / Cell Products (with Cell Community donor pool and Apheresis Center) High-quality human starting materials for cell therapies including leukopaks, G-CSF mobilized blood stem cells, cord blood, bone marrow samples, and whole blood, collected under GxP conditions and customizable based on donor specifications (age, gender, BMI, HLA data, infectious disease markers). Used by pharma, biotech, academic, and transplant center clients for research, clinical trials, and commercial cell therapy production.
  • Manufacturing of ATMPs/CGT Products GMP-compliant contract development and manufacturing of cell and gene therapy products (ATMPs/CGT) for clinical trials and commercial use. Includes process development and optimization, process validation, genetic modification using viral vectors or CRISPR/Cas9, cell expansion, fill & finish, cryopreservation, and Qualified Person (QP) batch certification. Cellex currently manufactures 4 final drug products (FDPs) and 7 cellular intermediates for clients.
  • Supply Chain & Logistics (CMT) Central coordination through Cellex Manufacturing Transports and Logistics (CMT) provides product labeling, release documentation, archiving management, and temperature-controlled transport at ambient, +2 to +8°C, +15 to +25°C, -80°C, and -196°C with 24/7 shipment tracking, GDP/GxP compliance, and validated transport processes. Over 40,000 cell transport shipments have been completed.
  • Consultancy & Audits Regulatory consulting and audit services covering GMP/GxP compliance, EMA and FDA guidelines, genetic manipulation with viral vectors and CRISPR/Cas9, audit services for apheresis centers, quality management system creation, and clinical trial planning support. Over 150 audits have been carried out by Cellex's consulting team.

Quantifiable outcome

  • 3 approved CAR-T therapies manufactured in Cellex facilities in Europe
  • +5 more outcomes

Companies that use Cellex

Customer profile

Named customers6 records

Segments5 records

Ideal customer profiles4 records

Cellex technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Cellex partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core, minor and flagship.

  • Swarm OncologycoreStrategic or Co-development Partner · 5 March 2026Cellex completed GMP technology transfer to Cellex Cell Professionals GmbH for Swarm Oncology, securing German Manufacturer's Authorisation enabling GMP-compliant clinical-grade drug product manufacturing. This partnership positions Swarm Oncology to initiate its first-in-human clinical study for T cell therapies targeting advanced solid cancers.
  • Catalent (partnering with Cartherics)minorOthers · 1 January 2025Catalent expanded its agreement with Cartherics for iPSC-derived CAR-NK cell therapies. While this partnership does not directly involve Cellex, it is noted as a key development in the broader cell and gene therapy CDMO market that Cellex operates within.
  • Oxford Biomedica (partnering with Bristol Myers Squibb)minorOthers · 1 January 2025Oxford Biomedica entered a multi-year supply agreement with Bristol Myers Squibb for lentiviral vectors for CAR-T programs. This is noted as a key development in the broader cell and gene therapy CDMO market context.
  • AvenCell TherapeuticsflagshipStrategic or Co-development Partner · 1 January 2021AvenCell Therapeutics was co-founded in 2021 by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics, with registered offices in Boston, USA and Dresden, Germany. The company focuses on the development of allogeneic universal CAR-T cell therapies for immuno-oncology. Cellex participates as a manufacturing and strategic partner in this joint venture.

Scale indicators10 records

Recent moves13 records

Expansion highlights6 records

Cellex competitors and assessment

Company assessment

Broad incumbents

  • Lonza: Lonza is one of the world's largest CDMOs with a substantial cell and gene therapy manufacturing offering, including autologous and allogeneic capabilities. It is a direct competitor for Cellex's commercial and clinical-scale cell therapy manufacturing business, with broader geographic reach and significantly larger capacity.
  • Catalent: Catalent (acquired by Novo Holdings in 2024 for ~$16.5B) is a major global CDMO with dedicated cell therapy manufacturing services. It competes head-to-head with Cellex for CAR-T and other cell therapy sponsors, and was specifically cited as a comparable market participant in Cellex's competitive landscape.
  • Fujifilm Diosynth Biotechnologies: Fujifilm Diosynth is a large global CDMO that has invested in cell and gene therapy manufacturing capacity, including viral vector and cell therapy services. It competes with Cellex for large pharma cell therapy manufacturing contracts.
  • Thermo Fisher Scientific (Patheon): Thermo Fisher's pharma services division (including legacy Patheon) offers cell therapy and viral vector CDMO capabilities. As one of the largest life sciences tools and services providers, it competes with Cellex on integrated cell therapy offerings, particularly for clinical and commercial-scale programs.
  • Charles River Laboratories: Charles River provides cell and gene therapy CDMO services through its Biologics Solutions segment. It serves similar biotech and pharma customers developing advanced therapies, including starting material and manufacturing services comparable to Cellex's offerings.
  • WuXi Advanced Therapies: WuXi AppTec's Advanced Therapies unit is a major cell and gene therapy CDMO with large-scale manufacturing capabilities. It competes with Cellex for global cell therapy programs, though geopolitical considerations may limit overlap with certain Western sponsors.

Direct peers

  • Oxford Biomedica: Oxford Biomedica is a UK-based cell and gene therapy CDMO specializing in lentiviral vector manufacturing and has signed multi-year supply agreements (e.g., with Bristol Myers Squibb for CAR-T). It is one of the closest European peers to Cellex, operating in the same niche with similar CAR-T focus.
  • AGC Biologics: AGC Biologics is a global CDMO with cell and gene therapy manufacturing capabilities, including autologous and allogeneic services. It serves as a direct mid-sized competitor to Cellex in the European and global cell therapy CDMO market.
  • Rentschler Biopharma: Rentschler Biopharma is a German/European CDMO with cell and gene therapy capabilities, including viral vector manufacturing. It is a geographically and operationally similar mid-sized European peer to Cellex.
  • Minaris Regenerative Medicine: Minaris (formerly Hitachi Chemical Advanced Therapeutics Solutions) is a dedicated cell therapy CDMO focused on autologous and allogeneic cell therapy manufacturing. It is a closely comparable mid-sized specialist peer to Cellex.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Cellex social profiles

Digital presence

Cellex financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellex leadership team

Management profile

Number of profiles

Profiles7 records

Cellex subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

Cellex funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellex M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellex

What does Cellex do?

Cellex is a full-service Contract Development and Manufacturing Organization (CDMO) for cell and gene therapy products, providing GMP-compliant manufacturing of ATMPs/CGT products for clinical trials and commercial use. The company offers autologous and allogeneic cell collection from donors (Cell Community donor pool, apheresis center), process development, optimization, validation, genetic modification, fill & finish, cryopreservation, QP batch certification, temperature-controlled logistics via CMT, and regulatory consultancy including GMP audits for pharma, biotech, and academic clients.

Is Cellex a public or private company?

Cellex is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Cellex founded?

Cellex was founded in 2001. It employs 101 to 250 people.

Where is Cellex based?

Cellex is headquartered in Köln, Germany, in the Europe region.

How does Cellex make money?

One revenue line is on record: contract Manufacturing Services (CDMO).

Who are Cellex's main competitors?

Broad incumbents on record are Lonza, Catalent, Fujifilm Diosynth Biotechnologies, Thermo Fisher Scientific (Patheon), Charles River Laboratories and WuXi Advanced Therapies. Direct peers are Oxford Biomedica, AGC Biologics, Rentschler Biopharma and Minaris Regenerative Medicine.

Does Cellex have an API?

No public API is recorded for Cellex.

What industry is Cellex in?

Cellex's product category is Cell and Gene Therapy CDMO Services. Its primary akta.pro industry code is HLAGAGAA, Cell Therapy CDMO (Autologous/Allogeneic Manufacturing), with a secondary code of HLAAAKAC, Cell Therapy Manufacturing Services (GMP, autologous/allogeneic). Its NAICS code is 621991 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Business & Financial100+ Cell And Gene Therapy Experts Meet In Cologne As Cellex Marks 25 YearsCellex Cell Professionals hosted its 25th-anniversary symposium in Cologne on November 8, bringing over 100 experts to discuss cell and gene therapy. The event featured 10 presentations across three sessions, covering translation, targeting, and market reality, and highlighted Cellex's growth from apheresis services to a CDMO.PR NewswireMehr als 100 Experten für Zell- und Gentherapie treffen sich in Köln anlässlich des 25-jährigen Jubiläums der CellexCellex Cell Professionals hosted the Cellex Symposium 2026 in Cologne on November 8, bringing over 100 experts to mark its 25th anniversary. The event covered cell and gene therapy from research to commercialization, with sessions on clinical translation, targeting, and market reality. Cellex has evolved from a stem cell donor registry service to a CDMO for cell therapies.PR NewswirePlus de 100 experts en thérapie cellulaire et génique se réunissent à Cologne à l'occasion des 25 ans de CellexCellex Cell Professionals hosted a colloquium in Cologne on November 8, 2026, with over 100 experts, marking its 25th anniversary. The event covered cell and gene therapy from research to commercialization, with sessions on clinical translation, targeting, and market reality.PR NewswireMás de 100 expertos en terapia celular y génica reunidos en Colonia con motivo del 25º aniversario de CellexCellex Cell Professionals hosted the Simposio Cellex 2026 in Colonia, Germany, on November 8, bringing together over 100 experts in cellular and gene therapy. The event marked the company's 25th anniversary, transitioning from apheresis services to a CDMO specializing in cellular therapy manufacturing.PR Newswire100+ Cell and Gene Therapy Experts Meet in Cologne as Cellex Marks 25 YearsCellex Cell Professionals hosted the Cellex Symposium 2026 in Cologne on November 8, bringing over 100 experts to discuss cell and gene therapy. The event marked the company's 25th anniversary, transitioning from apheresis services to a cell therapy CDMO. The symposium covered sessions on translation, targeting, and market reality.PR Newswire100+ Cell and Gene Therapy Experts Meet in Cologne as Cellex Marks 25 YearsCellex Cell Professionals hosted the Cellex Symposium 2026 in Cologne on November 8, bringing over 100 experts to discuss cell and gene therapy. The event marked the company's 25th anniversary, transitioning from apheresis services to a cell therapy CDMO. The symposium covered research, manufacturing, and commercialization, with Cellex looking forward to continued partnerships.PR NewswireCellex Cell Professionals Surpasses 10,000 Autologous ATMP Manufacturing BatchesCellex Cell Professionals surpassed 10,000 autologous ATMP manufacturing batches for 12 clinical and commercial partner programs. Each batch is patient-specific, requiring coordinated collection, manufacturing, testing, and logistics. The company will continue investing in capabilities for complex cell therapies.PR NewswireCellex Cell Professionals überschreitet die Marke von 10.000 autologen ATMP-ProduktionschargenCellex Cell Professionals surpassed 10,000 autologous production lots for ATMPs, made for 12 clinical and commercial partner programs. Each lot is patient-specific, requiring coordinated manufacturing and logistics. The company will continue investing in capacity for complex cell therapy programs.PR NewswireCellex Cell Professionals dépasse les 10 000 lots de fabrication de médicaments de thérapie innovante autologuesCellex Cell Professionals surpassed 10,000 autologous drug lots for 12 partner programs. Each lot is prepared for a single patient, requiring strict quality and logistics control. The company continues investing in clean rooms to support complex cell therapies.PR NewswireCellex Cell Professionals Surpasses 10,000 Autologous ATMP Manufacturing BatchesCellex Cell Professionals surpassed 10,000 autologous ATMP manufacturing batches for 12 clinical and commercial partner programs. Each batch is patient-specific, requiring coordinated collection, manufacturing, testing, and logistics. The company will continue investing in capabilities for complex cell therapies.